Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: A clinical trial

International Journal of Medical Sciences

Volumn 6, Issue 6, 2009, Pages 312-321

  Crowley, David C ^a   Lau, Francis C ^b   Sharma, Prachi ^a   Evans, Malkanthi ^a   Guthrie, Najla ^a   Bagchi, Manashi ^b   Bagchi, Debasis ^b,c   Dey, Dipak K ^d   Raychaudhuri, Siba P ^e,f  

^a KGK Synergize Inc   (Canada)

^b InterHealth Nutraceuticals Inc   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chondroitin; Glucosamine; Lequesne's functional index; Osteoarthritis; Undenatured type II collagen; Visual analog scale; WOMAC

Indexed keywords

CHONDROITIN; COLLAGEN TYPE 2; GLUCOSAMINE; UNCLASSIFIED DRUG; UNDENATURED COLLAGEN TYPE 2;

ADULT; AGED; ARTICLE; BLEEDING; BLOATING; BLOOD DISEASE; BONE MARROW DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; EAR DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INFECTION; KNEE OSTEOARTHRITIS; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; PAIN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SKIN DISEASE; SOFT TISSUE DISEASE; STOMACH PAIN; TREATMENT OUTCOME; URTICARIA; VISUAL ANALOG SCALE; VISUAL DISORDER; WATER RETENTION;

EID: 74549119454     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.6.312     Document Type: Article

References (22)

1. Braham R, Dawson B, Goodman C. The effect of glucosamine supplementation on people experiencing regular knee pain. Br J Sports Med 2003; 37:4549.
2. Cote LG. Management of osteoarthritis. J Am Acad Nurse Pract 2001; 13:495-501.
3. [Internet] Arthritis Foundation. http://www.arthritis.org/conditions/ DiseaseCenter/default.asp
4. ANON. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arth Rheum 2000; 43:1905-1915.
5. Haq I, Murphy E, Dacre J. Osteoarthritis. Postgrad Med J 2003; 79:377-383.
6. Brown LP. Pet Nutraceuticals; Inter-Cal Nutraceuticals. US: Arthritis Foundation. 2005.
7. Bruyere O, Reginster JY. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007; 24:573-580.
8. Barnett ML, Kremer JM, St Clair EW, Clegg DO, Furst D, Weisman M, Fletcher MJ, Chasan-Taber S, Finger E, Morales A, Le CH, Trentham DE. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998; 41(2):290-7.
9. Barnett ML, Combitchi D, Trentham DE. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 1996; 39(4):623-8.
10. Trentham DE. Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis. Ann N Y Acad Sci 1996; 778:306-14.
11. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, Hafler DA, Weiner HL. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261(5129):1727-30.
12. Bagchi D, Misner B, Bagchi M, Kothari SC, Downs BW, Fafard RD, Preuss HG. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res 2002; 22(3-4):101-10.
13. Deparle LA, Gupta RC, Canerdy TD, Goad JT, D'Altilio M, Bagchi M, Bagchi D. Efficacy and safety of glycosylated undenatured type-II collagen (UC-II) in therapy of arthritic dogs. J Vet Pharmacol Ther 2005; 28(4):385-90.
14. D'Altilio M, Peal A, Alvey M, Simms C, Curtsinger A, Gupta RC, Canerdy TD, Goad J, Bagchi M, Bagchi D. Therapeutic efficacy and safety of undenatured type II collagen singly or in combination with glucosamine and chondroitin in arthritic dogs. Tox Mech Methods 2007; 17:189-196.
15. Faria AM, Weiner HL. Oral tolerance. Immunol Rev 2005; 206:232-59.
16. COSTART: Coding symbol thesaurus for adverse reaction terms. 3rd ed. Rockville, MD: Center for Drugs and Biologics, Division of Drug and Biological Products Experience, 1989.
17. Bellamy N, Watson Buchanan W, Goldsmith CH, Campbell J, Stitt LW. 1988. Validation study for WOMAC: health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15:1833-1840.
18. Lequesne MG, Mery C, Samson M, Gerard P: Indexes of severity for osteoarthritis of the hip and knee validation-value in comparison with other assessment tests. Scand J Rheumatol 1987; 65:85-9.
19. Felson DT. The epidemiology of knee osteoarthritis: Results from the Framingham Osteoarthritis Study. Semin Arthritis Rheum 1990; 20:42-50.
20. Van Sasse JL, van Romunde LK, Cats A, Vanderbroucke JP. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 1989; 48(4):271-80.
21. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, Chondroitin Sulfate, and the Two on Combination for Painful Knee Osteoarthritis. N Engl J Med 2006; 354(8): 795-808.
22. Gupta RC, Bagchi D, Skaggs P, Burke R, Wegford K, Goad JT, Canerdy TD, Barnett D and Bagchi M. Therapeutic efficacy of undenatured type-II collagen (UC-II) in comparison to glucosamine and chondroitin in arthritic horses. J Vet Pharmacol Ther 2008; in press.